Watchlist · 78/100Aug 6, 7:45 PM EDT
Natera Projects 2026 Revenue of $2.85B-$2.91B, Fueled by 31% Core Growth and Record Test Volumes
NTRA
Natera (NTRA) guided 2026 revenue to $2.85B-$2.91B, representing 31% growth excluding true-ups, driven by record Q2 test volumes of ~1.044M and strong oncology momentum with 283,000 MRD units (up ~56% YoY). The outlook underscores robust demand across its test…
- ▹Strong revenue growth and record test volumes, especially in MRD oncology, indicate robust commercial traction.
- ▹Platform technology with multiple tests and recent FDA clearances support a positive regulatory outlook.
Watchlist · 75/100Aug 6, 7:25 PM EDT
Halozyme Raises 2026 Revenue Forecast, Projects EPS of $8.65-$9.00
HALO
Halozyme Therapeutics (HALO) raised its 2026 revenue outlook to $1.835B-$1.91B and projects non-GAAP EPS of $8.65-$9.00, driven by ENHANZE royalty growth and new deal momentum. The company highlighted strong upfront milestones and the early success of Hypercon…
- ▹Strong ENHANZE royalty growth and raised guidance indicate commercial traction.
- ▹Platform technology with multiple partnerships supports technology score, but single-asset focus and dilution risk temper narrative.
Watchlist · 74/100Aug 6, 5:51 PM EDT
Replimune's Tudriqev Wins FDA Accelerated Approval for Melanoma Combo
REPLBMY
Replimune (REPL) received FDA accelerated approval for its gene therapy Tudriqev, used with Bristol Myers Squibb's (BMY) Opdivo, as a second-line treatment for cutaneous melanoma. This approval, based on the I trial results, marks a significant milestone for R…
- ▹Accelerated approval with surrogate endpoint and no recent FDA negatives.
- ▹Platform gene therapy with combination use, but single-asset focus and early commercial stage.
Watchlist · 70/100Aug 6, 6:45 PM EDT
Immunocore Sets TEBE-AM Data Readout for Late 2026, Aims to Boost KIMMTRAK Capacity Beyond 1,000 Patients Annually
IMCR
Immunocore (IMCR) plans to release TEBE-AM data by the end of 2026, a key catalyst for its pipeline. The company is also scaling up production of its lead drug KIMMTRAK to treat over 1,000 patients per year, signaling confidence in growing demand and commercia…
- ▹KIMMTRAK is commercialized and growing, with expansion beyond 1,000 patients per year, indicating strong demand.
- ▹Pipeline progress with TEBE-AM data expected end of 2026, but single-asset focus and long timeline to data cap upside.
Watchlist · 69/100Aug 6, 6:25 PM EDT
Novavax Projects 2026 Revenue of $235M-$275M, Sets 2028 Cost Target of $150M-$200M
NVAX
Novavax (NVAX) guided to adjusted total revenue of $235M-$275M for 2026, while targeting non-GAAP R&D and SG&A expenses of $150M-$200M in 2028. Management emphasizes a lean, partnership-driven model to improve capital efficiency, which could signal a path to p…
- ▹Guidance for 2026 revenue and cost targets indicates a leaner, partnered model, but no specific regulatory catalysts.
- ▹Platform technology and partnerships provide some moat, but single-asset focus and dilution risk cap upside.
Watchlist · 65/100Aug 6, 5:16 PM EDT
Regenxbio's Cash Runway Extends to Late 2027 as RGX-202 BLA Filing Targeted for Q3 2026
RGNX
Regenxbio (RGNX) announced during its Q2 2026 earnings call that it has sufficient cash to fund operations into Q4 2027, with a key milestone being the planned module 1 BLA filing for RGX-202 in Q3 2026. The company also completed enrollment in the confirmator…
- ▹RGX-202 confirmatory study fully enrolled with FDA alignment, targeting BLA filing in Q3 2026, indicating regulatory clarity and progress.
- ▹Cash runway into Q4 2027 reduces near-term dilution risk, but single-asset focus and lack of commercial revenue cap upside.
Neutral · 62/100Aug 6, 4:36 PM EDT
Intellia Projects Cash Runway to 2028, Eyes Early 2027 U.S. Launch for Lonvo-z
NTLA
Intellia Therapeutics (NTLA) reported strong progress in its Phase III programs for lonvo-z (HAE) and nex-z (ATTR), with CEO John Leonard citing HAELO data as a key milestone. The company expects its cash runway to extend into 2028, supporting a potential U.S.…
- ▹Phase III data for lonvo-z positions for potential approval, but regulatory path not yet secured.
- ▹Cash runway into 2028 provides stability, but single-asset focus and pre-commercial stage cap upside.
Neutral · 59/100Aug 6, 4:26 PM EDT
Roivant Sets Brepocitinib Launch for Late September, Eyes 2028 Phase III Readout in Cutaneous Sarcoidosis
ROIV
Roivant Sciences (ROIV) plans to launch brepocitinib for dermatomyositis by the end of September, with a pivotal Phase III trial in cutaneous sarcoidosis expected to report data in 2028. Management characterized Q1 2026 as a quiet period ahead of a busy second…
- ▹Brepocitinib launch imminent but single-asset focus and no FDA clarity yet
- ▹Dermatomyositis launch and sarcoidosis Phase III data are key catalysts
Neutral · 55/100Aug 6, 5:05 PM EDT
Ocugen's FDA Greenlight for OCU410 Phase III and Extended Cash Runway Pave Way for Three BLAs by 2028
OCGN
Ocugen (OCGN) received FDA clearance to initiate a Phase III trial for OCU410 in geographic atrophy, a key milestone for the company. With a cash runway extending into 2028, Ocugen plans to file three Biologics License Applications (BLAs) by 2028, positioning…
- ▹FDA clearance for Phase 3 OCU410 is a positive regulatory step, but no accelerated path or surrogate endpoint mentioned.
- ▹Single-asset focus and early-stage pipeline cap technology and commercial scores; cash runway into 2028 is a positive narrative.
High Risk · 47/100Aug 6, 4:36 PM EDT
Zai Lab Eyes 2028 Zoci Approval, Aims for Three Registrational Programs by Year-End
ZLAB
Zai Lab (ZLAB) announced during its Q2 2026 earnings call that it expects approval for its drug Zoci in 2028, with its first U.S. regulatory submission planned for next year. The company is targeting three registrational programs by the end of the year, markin…
- ▹Zoci approval expected in 2028, indicating long timeline and regulatory uncertainty.
- ▹Transition to global biopharma with first U.S. submission next year, but single-asset focus and dilution risk.
High Risk · 30/100Aug 6, 5:34 PM EDT
Trump Reportedly Plans Executive Order Linking Vaccines to Autism
MRKGSK
President Trump is reportedly considering an executive order on vaccines and autism, potentially as soon as next week, amid frustration over inaction. This could impact vaccine makers like Merck (MRK) and GSK, as any policy shift may affect vaccine mandates, p…
- ▹Potential executive order could disrupt vaccine policy and create regulatory uncertainty for vaccine makers.
- ▹News is speculative and negative for vaccine sentiment; no direct company-specific catalyst.